Sitari Pharmaceuticals

San Diego
United States

NextGen Class of 2015
Show jobs for this employer

About Sitari Pharmaceuticals

Sitari Pharmaceuticals, Inc. develops treatments for multiple disease indications such as celiac disease. The company offers targeted inhibitors of Transglutaminase 2 (TG2) with the potential to suppress the autoimmune response that results in intestinal inflammation and cell pathogenesis in celiac patients. Sitari Pharmaceuticals, Inc. was founded in 2013 and is based in San Diego, California.

2 articles about Sitari Pharmaceuticals